{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:55:31Z","timestamp":1791302131976,"version":"4.1.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Recently, the global emergence of emergomycosis, a systemic fungal infection caused by a novel dimorphic fungus\n                    <jats:italic>Emergomyces<\/jats:italic>\n                    species has been observed among immunocompromised individuals. Though initially classified under the genus\n                    <jats:italic>Emmonsia<\/jats:italic>\n                    , a taxonomic revision in 2017 based on DNA sequence analyses placed five\n                    <jats:italic>Emmonsia<\/jats:italic>\n                    -like fungi under a separate genus\n                    <jats:italic>Emergomyces<\/jats:italic>\n                    . These include\n                    <jats:italic>Emergomyces pasteurianus, Emergomyces africanus, Emergomyces canadensis, Emergomyces orientalis<\/jats:italic>\n                    , and\n                    <jats:italic>Emergomyces europaeus<\/jats:italic>\n                    .\n                    <jats:italic>Emmonsia parva<\/jats:italic>\n                    was renamed as\n                    <jats:italic>Blastomyces parvus<\/jats:italic>\n                    , while\n                    <jats:italic>Emmonsia crescens<\/jats:italic>\n                    and\n                    <jats:italic>Emmonsia sola<\/jats:italic>\n                    remained within the genus\n                    <jats:italic>Emmonsia<\/jats:italic>\n                    until a taxonomic revision in 2020 placed both the species under the genus\n                    <jats:italic>Emergomyces<\/jats:italic>\n                    . However, unlike other members of the genus,\n                    <jats:italic>Emergomyces crescens<\/jats:italic>\n                    and\n                    <jats:italic>Emergomyces sola<\/jats:italic>\n                    do not cause disseminated disease. The former causes adiaspiromycosis, a granulomatous pulmonary disease, while the latter has not been associated with human disease. So far, emergomycosis has been mapped across four continents: Asia, Europe, Africa and North America. However, considering the increasing prevalence of HIV\/AIDS, it is presumed that the disease must have a worldwide distribution with many cases going undetected. Diagnosis of emergomycosis remains challenging. It should be considered in the differential diagnosis of histoplasmosis as there is considerable clinical and histopathological overlap between the two entities. Sequencing the internal transcribed spacer region of ribosomal DNA is considered as the gold standard for identification, but its application is compromised in resource limited settings. Serological tests are non-specific and demonstrate cross-reactivity with\n                    <jats:italic>Histoplasma<\/jats:italic>\n                    galactomannan antigen. Therefore, an affordable, accessible, and reliable diagnostic test is the need of the hour to enable its diagnosis in endemic regions and also for epidemiological surveillance. Currently, there are no consensus guidelines for the treatment of emergomycosis. The recommended regimen consists of amphotericin B (deoxycholate or liposomal formulation) for 1\u20132 weeks, followed by oral itraconazole for at least 12 months. This review elaborates the taxonomic, clinical, diagnostic, and therapeutic aspects of emergomycosis. It also enumerates several novel antifungal drugs which might hold promise in the treatment of this condition and therefore, can be potential areas of future studies.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.670731","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T11:26:43Z","timestamp":1619177203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Emergomycosis, an Emerging Systemic Mycosis in Immunocompromised Patients: Current Trends and Future Prospects"],"prefix":"10.3389","volume":"8","author":[{"given":"Arghadip","family":"Samaddar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12281-018-0308-y","article-title":"Emergomyces: a new genus of dimorphic fungal pathogens causing disseminated disease among immunocompromised persons globally","volume":"12","author":"Schwartz","year":"2018","journal-title":"Curr Fungal Infect Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/myc.12601","article-title":"Novel taxa of thermally dimorphic systemic pathogens in the Ajellomycetaceae (Onygenales)","volume":"60","author":"Dukik","year":"2017","journal-title":"Mycoses."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1007977","DOI":"10.1371\/journal.ppat.1007977","article-title":"Emergomyces: the global rise of new dimorphic fungal pathogens","volume":"15","author":"Schwartz","year":"2019","journal-title":"PLoS Pathog."},{"key":"B4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13225-018-0403-y","article-title":"Phylogeny, ecology and taxonomy of systemic pathogens and their relatives in Ajellomycetaceae (Onygenales): Blastomyces, Emergomyces, Emmonsia, Emmonsiellopsis","volume":"90","author":"Jiang","year":"2018","journal-title":"Fungal Divers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e01661","DOI":"10.1128\/JCM.01661-19","article-title":"Human blastomycosis in south africa caused by blastomyces percursus and Blastomyces emzantsi sp. nov., 1967 to 2014","volume":"58","author":"Maphanga","year":"2020","journal-title":"J Clin Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s11046-020-00475-4","article-title":"Intraspecific diversity and taxonomy of Emmonsia crescens","volume":"185","author":"Jiang","year":"2020","journal-title":"Mycopathologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3201\/eid2402.171351","article-title":"Emergomyces africanus in Soil, South Africa","volume":"24","author":"Schwartz","year":"2018","journal-title":"Emerg Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1038\/s41598-018-22816-6","article-title":"Genome analysis reveals evolutionary mechanisms of adaptation in systemic dimorphic fungi","volume":"8","author":"Mu\u00f1oz","year":"2018","journal-title":"Sci Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s11046-020-00431-2","article-title":"Re-drawing the maps for Endemic mycosis","volume":"185","author":"Ashraf","year":"2020","journal-title":"Mycopathologia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11046-019-00353-8","article-title":"Molecular diagnosis of Emmonsia-like fungi occurring in wild animals","volume":"185","author":"Danesi","year":"2020","journal-title":"Mycopathologia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/1346-8138.12975","article-title":"Disseminated infection caused by Emmonsia pasteuriana in a renal transplant recipient","volume":"42","author":"Feng","year":"2015","journal-title":"J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamadermatol.2015.1792","article-title":"Cutaneous disseminated emmonsiosis due to Emmonsia pasteuriana in a patient with cytomegalovirus enteritis","volume":"151","author":"Tang","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/myc.12437","article-title":"Disseminated Emmonsia pasteuriana infection in India:a case report and a review","volume":"59","author":"Malik","year":"2016","journal-title":"Mycoses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11046-019-00387-y","article-title":"Disseminated Emergomyces pasteurianus infection in India: a case report and a review","volume":"185","author":"Capoor","year":"2020","journal-title":"Mycopathologia"},{"key":"B15","first-page":"57","article-title":"Cutaneous disseminated mycosis in a patient with AIDS due to a new dimorphic fungus","volume":"8","author":"Gori","year":"1998","journal-title":"J Mycol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.mycmed.2017.04.025","article-title":"Emmonsia pasteuriana: une cause rare d'infection fongique chez l'immunod\u00e9prim\u00e9","volume":"27","author":"Lavergne","year":"2017","journal-title":"J Mycol Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/tid.12214","article-title":"A second look at Emmonsia infection can make the difference","volume":"16","author":"Pelegr\u00edn","year":"2014","journal-title":"Transpl Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mmcr.2019.01.005","article-title":"Two cases of Emergomyces pasteurianus infection in immunocompromised patients in the Netherlands","volume":"24","author":"Gast","year":"2019","journal-title":"Med Mycol Case Rep."},{"key":"B19","first-page":"6","article-title":"Emergomycosis: case report of a disseminated Emergomyces pasteurianus infection and review of an emerging fungal infection. 52nd Scientific Conference of the German speaking Mycological Society (DMykG) together with the Austrian Society for Medical Mycology (\u00d6GMM)","author":"Wilmes","year":"2018"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1215460","article-title":"A dimorphic fungus causing disseminated infection in South Africa","volume":"369","author":"Kenyon","year":"2013","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3201\/eid2404.171765","article-title":"Emergomyces canadensis, a dimorphic fungus causing fatal systemic human disease in North America","volume":"24","author":"Schwartz","year":"2018","journal-title":"Emerg Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/myc.12583","article-title":"A novel dimorphic pathogen, Emergomyces orientalis (Onygenales), agent of disseminated infection","volume":"60","author":"Wang","year":"2017","journal-title":"Mycoses"},{"key":"B23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1078\/1438-4221-00281","article-title":"Chronic granulomatous lung infection caused by the dimorphic fungus Emmonsia sp","volume":"293","author":"Wellinghausen","year":"2003","journal-title":"Int J Med Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000497608","article-title":"Emergomyces africanus: the mimicking fungus","volume":"6","author":"Moodley","year":"2019","journal-title":"Dermatopathology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"ofx186","DOI":"10.1093\/ofid\/ofx186","article-title":"AIDS-related endemic mycoses in Western Cape, South Africa, and clinical mimics:a cross-sectional study of adults with advanced HIV and recent-onset, widespread skin lesions","volume":"4","author":"Schwartz","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/myc.13071","article-title":"Screening for invasive fungal disease using non-culture-based assays among in patients with advanced HIV disease at a large academic hospital in South Africa","volume":"63","author":"van Schalkwyk","year":"2020","journal-title":"Mycoses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/civ439","article-title":"Clinical characteristics, diagnosis, management and outcomes of disseminated emmonsiosis:a retrospective case series","volume":"61","author":"Schwartz","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0006174","DOI":"10.1371\/journal.pntd.0006174","article-title":"Molecular detection of airborne Emergomyces africanus, a thermally dimorphic fungal pathogen, in Cape Town, South Africa","volume":"12","author":"Schwartz","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/mmy\/myx065","article-title":"Attempted molecular detection of the thermally dimorphic human fungal pathogen Emergomyces africanus in terrestrial small mammals in South Africa","volume":"56","author":"Cronj\u00e9","year":"2018","journal-title":"Med Mycol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"fox069","DOI":"10.1093\/femsyr\/fox069","article-title":"First report of urease activity in the novel systemic fungal pathogen Emergomyces africanus: a comparison with the neurotrope Cryptococcus neoformans","volume":"17","author":"Lerm","year":"2017","journal-title":"FEMS Yeast Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2353\/ajpath.2009.080673","article-title":"Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung","volume":"174","author":"Osterholzer","year":"2009","journal-title":"Am J Pathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000495405","article-title":"Emergomycosis (Emergomyces africanus) in advanced HIV disease","volume":"6","author":"Govender","year":"2019","journal-title":"Dermatopathology"},{"key":"B33","article-title":"Infectious diseases of the skin","volume-title":"McKee's Pathology of the Skin With Clinical Correlations, 5th Edn","author":"Grayson","year":"2018"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0006173","DOI":"10.1371\/journal.pntd.0006173","article-title":"Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy","volume":"12","author":"Crombie","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"B35","first-page":"36","article-title":"Difficulties with molecular diagnostic tests for mould and yeast infections:where do we stand?","volume-title":"Clin Microbiol Infect.","author":"Alanio","year":"2014"},{"key":"B36","article-title":"Evaluation of a new Histoplasma spp. reverse transcriptase quantitative PCR assay","volume-title":"J Mol Diagn","author":"Alanio","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1128\/JCM.02524-16","article-title":"In vitro antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-infected South African Patients","volume":"55","author":"Maphanga","year":"2017","journal-title":"J Clin Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3201\/eid2509.181234","article-title":"Disseminated emergomycosis in a person with HIV infection, Uganda","volume":"25","author":"Rooms","year":"2019","journal-title":"Emerg Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/1471-2334-11-202","article-title":"Comparison of quantitative real time PCR with sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens","volume":"11","author":"Rickerts","year":"2011","journal-title":"BMC Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/mmy\/myy041","article-title":"Identification of Aspergillus and Mucorales in formalin-fixed, paraffin-embedded tissue samples: comparison of specific and broad-range fungal qPCR assays","volume":"57","author":"Springer","year":"2019","journal-title":"Med Mycol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"myaa100","DOI":"10.1093\/mmy\/myaa100","article-title":"Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa","volume":"2020","author":"Maphanga","year":"2020","journal-title":"Med Mycol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e01886","DOI":"10.1128\/AAC.01886-17","article-title":"Antifungal susceptibility of emerging dimorphic pathogens in the family Ajellomycetaceae","volume":"62","author":"Dukik","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/21505594.2016.1235653","article-title":"Antifungal therapeutics for dimorphic fungal pathogens","volume":"8","author":"Goughenour","year":"2017","journal-title":"Virulence"},{"key":"B44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal:alternative drugs and future targets","volume":"51","author":"Wiederhold","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"B46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline:a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ccm.2009.02.001","article-title":"Overview of antifungal agents","volume":"30","author":"Thompson","year":"2009","journal-title":"Clin Chest Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole:a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14740331003752694","article-title":"Interactions between antifungal and antiretroviral agents","volume":"9","author":"Hughes","year":"2010","journal-title":"Exp Opin Drug Saf."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/S1473-3099(17)30568-6","article-title":"Itraconazole and antiretroviral therapy:strategies for empiric dosing","volume":"17","author":"Schwartz","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/17425255.2013.794785","article-title":"Itraconazole:an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections","volume":"9","author":"Lestner","year":"2013","journal-title":"Exp Opin Drug Metab Toxicol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/03639045.2019.1583757","article-title":"Nanostructured cochleates: a multi-layered platform for cellular transportation of therapeutics","volume":"45","author":"Shende","year":"2019","journal-title":"Drug Dev Ind Pharm."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dkz303","article-title":"Clinical experience with new formulation SUBA\u00ae-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies","volume":"74","author":"Nield","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jgg.2015.04.004","article-title":"Pyrimidine metabolism: dynamic and versatile pathways in pathogens and cellular development","volume":"42","author":"Garavito","year":"2015","journal-title":"J Genet Genomics."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e00999","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e01715","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1128\/AAC.42.9.2371","article-title":"Efficacy of nikkomycin Z in the treatment of murine histoplasmosis","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/AAC.34.4.587","article-title":"Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis","volume":"34","author":"Hector","year":"1990","journal-title":"Antimicrob Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"myaa054","DOI":"10.1093\/mmy\/myaa054","article-title":"Potential use of Nikkomycin Z as an anti- Sporothrix spp. drug","volume":"2020","author":"Poester","year":"2020","journal-title":"Med Mycol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e02258","DOI":"10.1128\/AAC.02258-17","article-title":"The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"7115","DOI":"10.1128\/AAC.01061-16","article-title":"The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of Cryptococcosis","volume":"60","author":"Koselny","year":"2016","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.670731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T11:26:50Z","timestamp":1619177210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.670731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":69,"alternative-id":["10.3389\/fmed.2021.670731"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.670731","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"article-number":"670731"}}